The Legacy Devers Eye Institute in Portland, Oregon, is one of the few private, non-profit centers for ophthalmological care, research, and training in the United States.
He was the first to publish on retinal toxicity secondary to gentamicin (a common antibiotic), acute placoid chorioretinitis from syphilis, and neuroretinopathy from intravenous contrast media.
[9] The Institute's total endowment is now approximately twenty-five million dollars, held primarily by the Legacy Health Good Samaritan Foundation.
The Devers Eye Institute staff includes fourteen ophthalmologists, four physician fellows, two clinical optometrists, and four additional senior scientists performing research.
The Discoveries in Sight Research Laboratory is headed by Claude Burgoyne, M.D., 2015 winner of the American Glaucoma Society Clinician Scientist Award.
[11] The cornea service is headed by Mark Terry, M.D., 2016 recipient of the Eye Bank Association of America R. Townley Paton Award.